New Weight-Loss drug candidate ABBV-295 enters early human testing
NCT ID NCT07514260
First seen Apr 18, 2026
Summary
This early-stage study is testing a new drug called ABBV-295 in 24 healthy Japanese adults who are overweight or obese. The main goal is to check the drug's safety and how the body processes it. Participants receive injections of the drug or a placebo, and researchers monitor for side effects. This is a first step to see if the drug is safe enough for larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
CenExel ACT- Anaheim Clinical Trials /ID# 280879
RECRUITINGAnaheim, California, 92801, United States
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.